| 4:00–8:00 PM | Arrival and Registration | Colorado Ballroom Foyer |
| 6:00–8:00 PM | Welcome Mixer | Colorado Ballroom Foyer |
| 7:00–8:00 AM | Breakfast | Summit Gallery |
| 8:00–9:00 AM | Welcome and Keynote Address | Peaks 4 - 5 |
| * Laura M. Walker, Moderna Session Chair |
| * Paul W. H. I. Parren, Leiden University Medical Center Session Chair |
| Janine Schuurman, Lust for Life Science Mining Antibody Biology for Novel Functionalities and Therapeutic Antibody Development |
| 9:00–11:15 AM | Fine-Tuning Antibody Fc Function | Peaks 4 - 5 |
| * CM Hsieh, Gilead Sciences Session Chair |
| E. Sally Ward, University of Southampton The Science of FcRn: Tuning Antibody and Antigen Degradation |
| John R. Desjarlais, Xencor, Inc. Engineering Therapeutic Antibodies to Optimize Half-Life and Function |
| Jeanette H.W. Leusen, University Medical Center Utrecht Engineered IgA Antibody Therapeutics |
| Remy M Muts, UMC Utrecht Short Talk: Short Talk: Conversion of S. Aureus Specific IgG Into IgM Broadens the Reactivity to Other Bacterial Species |
| 9:30–9:50 AM | Coffee Break | Colorado Ballroom Foyer |
| 11:15–1:00 PM | Poster Setup | Peaks 1 - 3 |
| 11:15–5:00 PM | On Own for Lunch |
| 1:00–10:00 PM | Poster Viewing | Peaks 1 - 3 |
| 3:00–4:30 PM | Career Roundtable | Peaks 4 - 5 |
| Kartik Chandran, Albert Einstein College of Medicine Professor and Chair |
| Joy Yu Zuchero, Denali Therapeutics Inc Director and Principal Scientist |
| Jeanette H.W. Leusen, University Medical Center Utrecht Professor |
| George Voren, Curie.Bio Head of Founder Strategy and Operations |
| 4:30–5:00 PM | Coffee Available | Colorado Ballroom Foyer |
| 5:00–7:00 PM | Engineered Antibodies in Infectious Disease | Peaks 4 - 5 |
| * Jacqueline Kirchner, Bill & Melinda Gates Foundation Session Chair |
| Kartik Chandran, Albert Einstein College of Medicine Engineered Antibodies for Treating Emerging Viral Infections |
| Gary J. Nabel, ModeX Therapeutics Multispecific Immunotherapies for Infectious Disease |
| Galit Alter, Moderna, Inc. Unraveling Correlates of Immunity with Systems Serology in Drug Development and Vaccines |
| Michael P Doyle, AstraZeneca Short Talk: Short Talk: Broad Coverage of Antibiotic-Resistant Klebsiella Pneumoniae by Multi-Specific Antibodies Against the Lipopolysaccharide O-Antigen |
| Jiaxuan Cheng, Vaccine Research Center, NIAID/NIH Short Talk: Short Talk: Structural Insights into Multimeric Recognition by Glycan-Directed Broadly Neutralizing Antibodies Targeting HIV-1 Envelope Glycoprotein |
| 7:00–8:00 PM | Social Hour with Lite Bites | Peaks 1 - 3 |
| 7:30–10:00 PM | Poster Session 1 | Peaks 1 - 3 |
| 7:00–8:00 AM | Breakfast | Summit Gallery |
| 8:00–11:00 AM | Orchestrating Immune Defense Against Cancer by Antibody Engineering | Peaks 4 - 5 |
| * Diane Hollenbaugh, Bonum Therapeutics, Inc. Session Chair |
| Hans van der Vliet, Lava Therapeutics Bispecific Antibodies for Recruiting Alternative Immune Cells for Cancer Therapy |
| Jamie Spangler, Johns Hopkins University Engineering Antibodies and Fusion Proteins for Disease Targeting |
| Stephen A. Beers, University of Southampton Interplay Between the Tumor Microenvironment and the Antibody Fc in Optimizing Therapy |
| Mika Kamata-Sakurai, Chugai Pharmaceutical Conditional Activation of Protein Therapeutics in the Tumor Microenvironment’ |
| Pratik Bhojnagarwala, The Wistar Institute Short Talk: Short Talk: Customized Ovarian Cancer Therapy Using in vivo Assembled Bi-Specific Antibodies Targeting Her2 and FSHR |
| John T Mulligan, Bonum Therapeutics, Inc. Short Talk: Short Talk: A Novel Method for Generating Regulated Cytokine Therapeutics: Safety and Activity of a Conditionally Active cLAG3-IL2 in a Simple Antibody Format |
| 9:00–9:20 AM | Coffee Break | Colorado Ballroom Foyer |
| 11:00–1:00 PM | Poster Setup | Peaks 1 - 3 |
| 11:00–5:00 PM | On Own for Lunch |
| 1:00–10:00 PM | Poster Viewing | Peaks 1 - 3 |
| 2:30–4:30 PM | Workshop: Computational Antibody Engineering | Peak 4-5 |
| * Peter Tessier, University of Michigan Session Chair |
| * Peter Tessier, University of Michigan Predicting Antibody Developability using Interpretable Machine Learning |
| Fabian C Spoendlin, University of Oxford Improved Computational Epitope Profiling Using Structural Models Identifies a Broader Diversity of Antibodies that Bind to the Same Epitope |
| Tobias Hegelund Olsen, GSK Addressing the Antibody Germline Bias and its Effect on Language Models for Improved Antibody Design |
| Benjamin Rubin, Adaptive Biotechnologies Multi-Modal, Broadly Neutralizing Antibodies to SARS-CoV-2 and Influenza Discovered via High-Throughput Native Pairing of BCRs From Bulk B Cells |
| Brett Blakeley, Generate Biomedicines Industrializing Therapeutic Antibody Design. Generative AI Enables Intentional Antibody Engineering Over Random Chance Discovery |
| Ira Zaretsky, Weizmann Institute of Science From Mice to Men: Energy-Based Antibody Humanization |
| Mark Hutchinson, AstraZeneca Computational Optimization of an Anti-HEL Antibody Leads to Increased Antibody Thermostability and Affinity |
| Fernando Luis Barroso da Silva, University of Sao Paulo Computational Insights and New Strategies for Advanced Antibody Engineering |
| 4:30–5:00 PM | Coffee Available | Colorado Ballroom Foyer |
| 5:00–7:15 PM | Avidity Engineering and Antibody Cocktails | Peaks 4 - 5 |
| * Ellen Wagner, GigaGen Session Chair |
| Paul W. H. I. Parren, Leiden University Medical Center Avidity Engineering of Therapeutic Antibodies |
| Bruce Keyt, IGM Biosciences Multipecific, IgM-based, T Cell Engagers for Treating Cancer |
| Jean-Philippe Julien, Hospital for Sick Children Research Institute Avid and Multispecific Biologics for Global Health |
| Ira Mellman, Genentech, Inc. Rational Design of Combinatorial Targeting to Optimize Checkpoint Blockade |
| Alexandra Margaret Terry, Genmab Short Talk: Short Talk: Exploring Interaction Rules for Multispecific Targeting using the HexElect Antibody Format |
| 7:15–8:15 PM | Social Hour with Lite Bites | Peaks 1 - 3 |
| 7:30–10:00 PM | Poster Session 2 | Peaks 1 - 3 |
| 7:00–8:00 AM | Breakfast | Summit Gallery |
| 8:00–11:00 AM | Engineered Antibody Constructs in the Clinic | Peaks 4 - 5 |
| * Jonathan Davis, Creative Antibodies Session Chair |
| Koustubh Ranade, Immunocore Advances Beyond Monoclonal Antibodies |
| Laura M. Walker, Moderna Prophylaxis and Treatment of Infectious Disease with Half-Life Extended Neutralizing Antibodies |
| David P. Humphreys, UCB Pharma TRYBE: An Fc-Free Antibody Format with Three Monovalent Targeting Arms and Engineered for Long in vivo Half-Life |
| Jaileene Hernandez Escalante, Generate Biomedicines Short Talk: Short Talk: Development of a Machine Learning (ML) Designed Anti-TSLP Antibody for the Treatment of Asthma |
| Mark Kroenke, Amgen Short Talk: Short Talk: Translatability of Findings from Cynomolgus Monkey to Human Suggests a Mechanistic Role for IL-21 in Promoting Immunogenicity to an Anti-PD-1/IL-21 Mutein Fusion Protein |
| 9:00–9:20 AM | Coffee Break | Colorado Ballroom Foyer |
| 11:00–5:00 PM | On Own for Lunch |
| 4:30–5:00 PM | Coffee Available | Colorado Ballroom Foyer |
| 5:00–6:45 PM | Fast Forward: Promising New Technologies and Applications | Peaks 4 - 5 |
| * Anna Park, Sanofi Session Chair |
| Sai T. Reddy, ETH Zurich Rational Design of Antibody Therapeutics via Deep Learning |
| Joy Yu Zuchero, Denali Therapeutics Inc Brain Delivery of Therapeutic Proteins with Fc-Engineered Molecules |
| Garrett Rappazzo, Adimab LLC Short Talk: Short Talk: Rapid Engineering of Soluble T Cell Receptors for Enhanced Affinity via a High-Throughput Yeast-Based Platform |
| Fangzhu Zhao, University of California San Francisco Short Talk: Short Talk: Cytokine Receptor-Targeting Chimeras: Unveiling Dual Modalities for Targeted Protein Degradation and Immune Cell Engagement |
| 6:45–7:00 PM | Meeting Wrap-Up: Outcomes and Future Directions (Organizers) | Peaks 4 - 5 |
| 7:00–8:00 PM | Social Hour with Lite Bites | Peaks 1 - 3 |
| 8:00–9:00 PM | Trivia | Peaks 4-5 |
| 8:00–9:00 PM | Cash Bar | Peaks 1 - 3 |
| 7:00–11:59 PM | Departure |